Real-World Evidence (RWE) Opportunities to Enhance Local Decision-Making in Oncology for Emerging Markets: A Multi-Regional Oncologist & Payer Committee Perspective
Author(s)
Guarin A1, Bazarbashi S2, Chiu A3, Hamad A4, Lee SC5, Petracci F6, Stefani S7, Wong C8, Ghai C8
1Pfizer, Bogota, CUN, Colombia, 2King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia, 3AXA Hong Kong, Hong Kong, Hong Kong, 4Hamad Medical Corporation, Doha, DA, Qatar, 5National University Hospital, Singapore, Singapore, 6Instituto Alexander Fleming, Buenos Aires, Argentina, 7Clínica Stefani, Porto Alegre, Brazil, 8Blue Matter Consulting, New York, NY, USA
Presentation Documents
OBJECTIVES:
Most countries in Emerging Markets follow guidance from the FDA and EMA for RWE generation and use. In these countries, there is demand amongst healthcare stakeholders to grow regional RWE capabilities to support clinician, payer, and regulator decision-making in oncology. This presentation aims to provide: perspectives on the current oncology RWE landscape in these countries; identification and prioritization of high-impact RWE opportunities; and, considerations for implementing the highest-priority opportunity.METHODS:
The RWE Insights Committee in Oncology (RICO) for Emerging Markets was established to inform on high-impact RWE opportunities from 15 oncologist KOLs and 9 payer advisors, across 16 countries in Latin America, Africa and the Middle East, and Asia Pacific. Two sets of primary market research-based, panel-style workshops were conducted: first, to characterize the oncology RWE landscape and identify future opportunities for investment; second, to prioritize opportunities and ideate on implementation design.RESULTS:
When characterizing the oncology RWE landscape, panelists indicated: greatest familiarity with traditional study designs (cohort, cross-sectional), most frequently used real-world data sources (EMR, medical charts), and common RWE uses (understanding treatment options, guiding future research). Of the RWE opportunities, local population studies, value-based contracting, and a technology-enabled RWE platform were prioritized as most impactful. The platform envisioned would include a stable, cross-regional network of data sources (usually hospitals) for a defined tumor type (e.g., breast, lung) that offers on-demand, clinically-rich data for a sufficiently large patient sample.CONCLUSIONS:
Despite lacking widespread infrastructure, Emerging Market oncologists and payers have deep RWE expertise. Among them, likeminded stakeholders are eager to collaborate on designing and implementing RWE opportunities, like the technology-enabled RWE platform. Such opportunities would advance regional RWE capabilities, and further enable RWE use in local decision-making.Conference/Value in Health Info
Value in Health, Volume 26, Issue 6, S2 (June 2023)
Code
RWD58
Topic
Health Policy & Regulatory, Organizational Practices, Real World Data & Information Systems
Topic Subcategory
Distributed Data & Research Networks, Health Disparities & Equity
Disease
No Additional Disease & Conditions/Specialized Treatment Areas